Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TYMP | P19971 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468894 | 0.86 | ALDH1A1 (0.52) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL27302714 | 0.82 | KDM4E (0.36) | KDM4EALDH1A1 | |
| SCHEMBL1192172 | 0.79 | ALDH1A1 (0.43) | KDM4EALDH1A1ESR2SMN1; SMN2 | |
| SCHEMBL5475667 | 0.77 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL6774136 | 0.77 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL24456484 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1 | |
| SCHEMBL178299 | 0.75 | ALDH1A1 (0.36) | KDM4EALDH1A1 | |
| SCHEMBL17162540 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1 | |
| SCHEMBL16977515 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1 | |
| SCHEMBL5733 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070282-A | Pyrazole-1-carboxamides as RIP1 kinase inhibitors | 比西切姆有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2025037940-A1 | PYRAZOLE-1-CARBOXAMIDES AS RIP1 KINASE INHIBITORS | BISICHEM CO., LTD. (KR) | 2025-02-20 | — | — | WO | disclosed |
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2022-10-11 | — | — | US | disclosed |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-3750910-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV Healthcare UK(No.4) Limited (GB) | 2020-12-16 | — | — | EP | disclosed |
| EP-3750910-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV Healthcare UK(No.4) Limited (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2020-11-19 | — | — | US | disclosed |
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2020-11-19 | — | — | US | disclosed |
| US-10780102-B2 | Triterpenoids with HIV maturation inhibitory activity | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| WO-2015157483-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015157483-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150291655-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-20150291655-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-7781469-B2 | Arylacetate derivatives having isoxazole skeleton | SHIONOGI & CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| US-20090062531-A1 | Arylacetate Derivatives Having Isoxazole Skeleton | SHIONOGI & CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1296973-B1 | GUANIDINE DERIVATIVES OF QUINAZOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1887000-A1 | ARYLACETATE DERIVATIVE HAVING ISOXAZOLE SKELETON | Shionogi Co., Ltd. (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780102-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | KDM4E 2728/4885ALDH1A1 2104/4885ESR2 3343/4885 |
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | KDM4E 2728/4885ALDH1A1 2104/4885ESR2 3343/4885 |
| US-20090062531-A1 | Arylacetate Derivatives Having Isoxazole Skeleton | CYP2A7, CYP4X1, HAX1 | KDM4E 1460/4885ALDH1A1 877/4885ESR2 2658/4885 |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | CYP2F1, CYP21A2, CYP11B1 | KDM4E 134/4885ALDH1A1 254/4885ESR2 2824/4885 |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ABL1, FLT3, JAK2 | KDM4E 1156/4885ALDH1A1 3215/4885ESR2 3199/4885 |
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | KDM4E 2728/4885ALDH1A1 2104/4885ESR2 3343/4885 |
| US-20150291655-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | KDM4E 2728/4885ALDH1A1 2104/4885ESR2 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.